Kyverna Therapeutics Inc. (KYTX) stock has reached a new 52-week low, trading at $2.78, down 10.4% in the past week alone, as the biotechnology firm faces a challenging market environment. According ...

Tivic Health (TIVC) announced it has acquired worldwide exclusive license rights from Statera Biopharma (STAB) to the late-stage Toll-like ...

The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...